Celularity Revenue and Competitors
Estimated Revenue & Valuation
- Celularity's estimated annual revenue is currently $45.1M per year.
- Celularity received $250.0M in venture funding in February 2018.
- Celularity's estimated revenue per employee is $193,750
- Celularity's total funding is $400M.
Employee Data
- Celularity has 233 Employees.
- Celularity grew their employee count by -29% last year.
Celularity's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director Customer Service and Sales Support | Reveal Email/Phone |
2 | Executive Director Corporate Accounts | Reveal Email/Phone |
3 | SVP Corporate Operations | Reveal Email/Phone |
4 | Senior Security Officer | Reveal Email/Phone |
5 | VP, NK Therapy | Reveal Email/Phone |
6 | VP, Human Resources and Legal | Reveal Email/Phone |
7 | Head Quality (interim) | Reveal Email/Phone |
8 | VP | R&D | Degenerative Diseases | Reveal Email/Phone |
9 | SVP Finance and Controller | Reveal Email/Phone |
10 | SVP, Clinical Dev. Immunology and Drug Safety | Reveal Email/Phone |
Celularity Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $83.7M | 462 | 53% | N/A | N/A |
What Is Celularity?
POSTPARTUM PLACENTA: THE FOUNDATION OF OUR SCIENCE - Celularity scientists were the first to recognize the human placenta as an untapped resource for innovation, one which is the basis of Celularity innovations in immuno-oncology, hematology, and regenerative medicine. Our seminal discovery of unique stem, progenitor, and immune cells from the placenta is the foundation of our dominating intellectual property position. With proprietary platform technology and operational expertise to harness the power of this remarkable organ, we developed a deep therapeutic pipeline across a broad range of indications. AMPLIFYING THE BODYS ABILITY TO REGENERATE - Celularity combines innovative assets and research in cell therapy, functional regeneration, and biosourcing to develop leading therapeutic products and services that treat serious, life-threatening diseases. We are harnessing the unique cells and biomaterials from the postpartum placenta to provide therapies that amplify the body's ability to fight disease, heal, and regenerate itself. For more information visit our website at www.celularity.com
keywords:N/A
$400M
Total Funding
233
Number of Employees
$45.1M
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Celularity News
Celularity Inc. ... These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity...
Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address...
Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for COVID-19. The company, which has raised at least $290 million to date ...
A spinout of Celgene, Celularity made big news in February 2018, when it raised $250 million to accelerate development of its stem cell ...
WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing ...
Other Companies in Warren
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $92M | 237 | 3% | N/A |
#2 | $87.5M | 241 | 10% | N/A |
#3 | $56.6M | 245 | 2% | N/A |
#4 | $56.8M | 246 | 4% | N/A |
#5 | $75.4M | 255 | -3% | $14M |
Celularity Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-02-16 | $250.0M | Undisclosed | Multiple | Article |